2018

Copy number loss in SFMBT1 is common among Finnish and Norwegian patients with iNPH

Korhonen, VE

Ovid Technologies (Wolters Kluwer Health)

Tieteelliset aikakauslehtiartikkelit
© Authors
CC BY-NC-ND https://creativecommons.org/licenses/by-nc-nd/4.0/
http://dx.doi.org/10.1212/NXG.0000000000000291

https://erepo.uef.fi/handle/123456789/7295
Downloaded from University of Eastern Finland's eRepository
Copy number loss in *SFMBT1* is common among Finnish and Norwegian patients with iNPH

Ville E. Korhonen, BMed, Seppo Helisalmi, PhD, Aleks Jokinen, BMed, Ilari Jokinen, BMed, Juha-Matti Lehtola, BMed, Minna Oinas, MD, PhD, Kimmo Lönnrot, MD, PhD, Cecilia Avellan, MD, Anna Kotkansalo, MD, Janek Frantzen, MD, Ph.D, Jaakko Rinne, MD, PhD, Antti Ronkainen, MD, PhD, Mikko Kauppinen, MD, Antti Junkkari, MD, PhD, Mikko Hiltunen, PhD, Hilppa Soininen, MD, PhD, Mitja Kurki, PhD, Juha E. Jääskeläinen, MD, PhD, Anne M. Koivisto, MD, PhD, Hidenori Sato, MD, PhD, Takeo Kato, MD, PhD, Anne M. Remes, MD, PhD, Per Kristian Eide, MD, PhD, and Ville Leinonen, MD, PhD

Neurol Genet 2018;4:e291. doi:10.1212/NXG.0000000000000291

**Abstract**

**Objective**

To evaluate the role of the copy number loss in *SFMBT1* in a Caucasian population.

**Methods**

Five hundred sixty-seven Finnish and 377 Norwegian patients with idiopathic normal pressure hydrocephalus (iNPH) were genotyped and compared with 508 Finnish elderly, neurologically healthy controls. The copy number loss in intron 2 of *SFMBT1* was determined using quantitative PCR.

**Results**

The copy number loss in intron 2 of *SFMBT1* was detected in 10% of Finnish (odds ratio [OR] = 1.9, *p* = 0.0078) and in 21% of Norwegian (OR = 4.7, *p* < 0.0001) patients with iNPH compared with 5.4% in Finnish controls. No copy number gains in *SFMBT1* were detected in patients with iNPH or healthy controls. The carrier status did not provide any prognostic value for the effect of shunt surgery in either population. Moreover, no difference was detected in the prevalence of hypertension or T2DM between *SFMBT1* copy number loss carriers and noncarriers.

**Conclusions**

This is the largest and the first multinational study reporting the increased prevalence of the copy number loss in intron 2 of *SFMBT1* among patients with iNPH, providing further evidence of its role in iNPH. The pathogenic role still remains unclear, requiring further study.
Idiopathic normal pressure hydrocephalus (iNPH) is a late-onset progressive neurologic disease presenting typically with gait difficulties together with enlarged ventricles and tightened parasagittal cortical sulci, whereas other symptoms such as cognitive impairment and urinary incontinence are often present.1,2 Recently, the 2 available diagnostic guidelines1,2 have been criticized, and urgent revision and/or unification of the diagnostic manual have been requested.3–5

Patients with iNPH are characterized by abnormal CSF circulation and evidence of delayed cerebral clearance, as recently shown in an MRI CSF tracer study.6 Although there are no biomarkers to aid in the diagnostics, and the etiology of iNPH remains unclear, there is an increasing amount of proof indicating a potential genetic component in iNPH.7–12 The prevalence of familial iNPH, i.e., at least 2 patients with iNPH, in the first-degree relatives has been reported to range from 4.8% to 7%.10,11 Data also contain a pair of identical twins having iNPH11 and a family in which an autosomal dominant inheritance pattern is observed.9

A segmental copy number loss in the SFMBT1 gene was reported in Japan to be present in 50% of patients, who present concomitantly with clinical features of iNPH and enlarged ventricles,13 and in 26% of patients with iNPH, who experienced a positive shunt response.14 These results have previously not been confirmed outside of Japan and with sufficiently large cohorts. Our aim was to evaluate the prevalence of the copy number loss of SFMBT1 in patients with iNPH of Caucasian origin.

Methods

Standard protocol approvals, registrations, and patient consents

This study was conducted in the Department of Neurosurgery in Kuopio University Hospital, the Brain Research Unit of the University of Eastern Finland, and the Department of Neurosurgery, Oslo University Hospital, Rikshospitalet, Oslo, Norway, according to the Declaration of Helsinki. Kuopio University Hospital Research Ethics Board approved the study (5/2008 and 276/2016). In Norway, the study was approved by the Regional Committee for Medical and Health Research Ethics (REK) of Health Region South-East, Norway (2015/1313), and the Institutional Review Board of Oslo University Hospital (2015/8128).

The study consisted of 567 Finnish (mean age 70 years; SD 8.3; men: n = 254; table 1) and 377 Norwegian (mean age 68 years; SD 11; men: n = 190 (50%); table 2) patients with possible iNPH. All patients and controls provided their written informed consent.

All Finnish and Norwegian patients suspected of having iNPH have been clinically evaluated by a neurologist and a neurosurgeon. The patients were referred to a neurosurgeon by a neurologist if the patients were observed to have at least one of the core symptoms associated with iNPH, which include gait difficulties, cognitive impairment, and urinary incontinence together with enlarged ventricles (Evans Index >0.30)15 disproportionate to the size of the sulci of the cerebral convexities in MRI or CT imaging scans. In addition, most Finnish and Norwegian patients have undergone, as a prognostic test for shunt benefit, a 24-hour intraventricular pressure monitoring, spinal tap, extended lumbar drainage, or lumbar infusion test.

The Norwegian patients were diagnosed, and the decision to perform the shunt surgery was done following a previously published protocol,16 which included a clinical judgment of the severity of iNPH symptoms using a Oslo iNPH Grading Scale (ranging from 3 to 15),16 MRI or CT imaging scans for the evaluation of the ventriculomegaly, evaluation of comorbidities, and finally a diagnostic overnight ICP monitoring.

All the Finnish and Norwegian patients fulfilled the clinical diagnostic criteria for possible iNPH.1,2 The control group consisted of 508 (mean age 70 years; SD 5.1; male: n = 207) Finnish subjects acquired for neurogenetic studies. All subjects have undergone clinical and neuropsychological evaluation at 3-month follow-up.

Table 1 Clinical characteristics of the Finnish iNPH cohort

<table>
<thead>
<tr>
<th>Variables</th>
<th>Mean or no. of cases</th>
<th>SD or %</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cases</td>
<td>567</td>
<td></td>
</tr>
<tr>
<td>Sex (female)</td>
<td>312</td>
<td>54.9</td>
</tr>
<tr>
<td>Comorbidities</td>
<td></td>
<td></td>
</tr>
<tr>
<td>High arterial blood pressure</td>
<td>339/564</td>
<td>59.7</td>
</tr>
<tr>
<td>Diabetes</td>
<td>169/565</td>
<td>29.8</td>
</tr>
<tr>
<td>Age at shunta</td>
<td>71</td>
<td>7.9</td>
</tr>
<tr>
<td>Positive subjective shunt responseb</td>
<td>458/528</td>
<td>86.8</td>
</tr>
<tr>
<td>Positive objective shunt responsec</td>
<td>97/203</td>
<td>49</td>
</tr>
</tbody>
</table>

a Available for 551 patients.
b Clinical evaluation at 3-month follow-up.
c Calculated using the modified 12-point Kubo scale, in which 1-point decrease is considered to be clinically important.
testing lead by an experienced neurologist specialized in neurodegenerative conditions to exclude any signs of cognitive impairment (table 3).

Genomic DNA was extracted from venous blood samples using QIAamp DNA blood mini extraction kit (QIAGEN). The copy number loss/gain in the intron 2 region of SFMBT1 was detected using quantitative PCR (qPCR) and the delta-delta method as previously described.\(^\text{14}\) Our collaborator (T. Kato) provided a positive control sample, and a commercial negative control was used.

All statistical analyses were performed using SPSS statistic version 23 (IBM corp. USA). The \(\chi^2\) test was used for categorical dichotomous variables for groups >2. The Fisher exact test was used for pairwise comparison. \(p < 0.05\) was considered statistically significant.

Power calculations were completed before the execution of the research and were based on the results of the study by Sato et al.\(^\text{14}\) in which the expected prevalence was divided by a factor of 2 (26/2% = 13%). With a power of 0.85, \(p = 0.05\), the sample size was determined to be \(n \geq 362\). Both the Finnish and Norwegian iNPH cohorts and Finnish controls fulfill this requirement.

### Table 2 Clinical characteristics of the Norwegian iNPH cohort

<table>
<thead>
<tr>
<th>Variables</th>
<th>Mean or no. of cases</th>
<th>SD or %</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cases</td>
<td>377</td>
<td></td>
</tr>
<tr>
<td>Sex (female)</td>
<td>187/377</td>
<td>49.6</td>
</tr>
<tr>
<td>Shunt</td>
<td>297/377</td>
<td>78.8</td>
</tr>
<tr>
<td>Comorbidities</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Arterial hypertension</td>
<td>156/377</td>
<td>41.4</td>
</tr>
<tr>
<td>Diabetes</td>
<td>58/377</td>
<td>15.4</td>
</tr>
<tr>
<td>Age at shunt</td>
<td>69</td>
<td>9.9</td>
</tr>
<tr>
<td>Positive shunt response(^a)</td>
<td>258/297</td>
<td>86.95</td>
</tr>
<tr>
<td>No shunt response</td>
<td>39/297</td>
<td>13.1</td>
</tr>
<tr>
<td>Lost to follow-up</td>
<td>7/297</td>
<td>2.4</td>
</tr>
</tbody>
</table>

Abbreviation: iNPH = idiopathic normal pressure hydrocephalus.

\(^a\) Clinical evaluation at 6–12 months after surgery. Calculated using the Oslo NPH scale.\(^\text{16}\)

### Table 3 Finnish control characteristics

<table>
<thead>
<tr>
<th>Variables</th>
<th>Mean or no. of cases</th>
<th>SD or %</th>
</tr>
</thead>
<tbody>
<tr>
<td>Controls</td>
<td>508</td>
<td></td>
</tr>
<tr>
<td>Sex (female)</td>
<td>301</td>
<td>59.3</td>
</tr>
<tr>
<td>Age at inclusion</td>
<td>69.8</td>
<td>5.1</td>
</tr>
</tbody>
</table>

Data availability statement

According to Finnish law, the full individual clinical data set cannot be shared publicly. However, the data set can/will be shared by academic collaboration agreement upon request.

### Results

The copy number loss in SFMBT1 was detected in 9.9% of the Finnish patients with iNPH, in 21% of the Norwegian patients with iNPH, and in 5.4% of the Finnish controls (figures 1 and 2). Statistically significant difference was detected between Finnish and Norwegian patients with iNPH (\(p < 0.0001\)). No copy number gains in SFMBT1 were detected in Finnish or Norwegian patients with iNPH or healthy controls. In the Finnish iNPH cohort, 9/71 suspected familial patients, who are carriers for the copy number loss, were detected, and therefore, no aggregation of the copy number loss variant was observed in familial iNPH (12.1% vs 10%, \(p = 0.5\)). There was no significant difference in age at onset, sex, shunting prevalence, or shunt response between Finnish and Norwegian patients. In addition, no difference was detected in the prevalence of hypertension or T2DM between SFMBT1 copy number loss carriers and noncarriers (table 4) or in the frequency of the genetic variant between shunt-responsive and nonresponsive patients in either Finnish (odds ratio [OR] = 1.0, confidence interval [CI] 95% 0.44–2.4, \(p = 0.93\)) or Norwegian (OR = 0.68, CI 95% 0.31–1.5, \(p = 0.33\)) cohort.

### Discussion

This is the first study on the prevalence of the copy number loss in SFMBT1 among patients with iNPH of non-Asian origin. Although there are studies describing familial aggregation\(^\text{11}\) and even in some rare cases autosomal dominant inheritance pattern,\(^\text{9}\) SFMBT1 is the first gene to be associated with iNPH. Our findings are principally in line with the Japanese results providing compelling further evidence on the role of the copy number loss in SFMBT1 in iNPH.

The copy number loss in SFMBT1 is detected only in 10%–20% of the patients with iNPH, which would suggest that iNPH has both a polygenetic and multifactorial origin. Ethnicity seems to modify the prevalence of this genetic variant between Finnish and Norwegian iNPH patients but surprisingly is similar between selected Norwegian and Japanese populations. In addition, a small percentage of cognitively intact controls carry the variant providing further evidence on the copy number loss in SFMBT1 of being only a possible risk-increasing genotype. In the Japanese study, a small percentage of patients and controls were found to carry a copy number gain variant, but no statistically significant difference between patients with iNPH and controls was detected.\(^\text{14}\) Of interest, in the Nordic cohorts, no copy number gain variants were detected in either patients with iNPH or healthy controls. Therefore, it appears that the copy number loss in...
SFMBT1 is associated with iNPH, and the results are not influenced by genomic instability in the SFMBT1 intron region.

Hypertension, T2DM, schizophrenia, and Alzheimer disease are common among patients with iNPH.17–22 The present results could reflect a higher occurrence of hypertension and T2DM in iNPH, as previously demonstrated. However, in this study cohort, we found no statistically significant difference in the prevalence of hypertension or T2DM between SFMBT1 copy number loss carriers and noncarriers, further validating its independent association with iNPH.

In the present study, both shunt-responsive and nonresponsive patients were included, and no difference was observed between these groups regarding the carrier status of the copy number loss in SFMBT1. The original discovery was done in subjects with enlarged brain ventricles,13 and the Japanese study on copy number loss in SFMBT114 included only shunt-responsive iNPH patients, and therefore, the prevalence of the copy number loss in SFMBT1 among patients who are nonresponsive to shunt surgery is unknown in the Japanese population.14 Because of the similar prevalence between both shunt-responsive and nonresponsive patient groups, SFMBT1 seems to be linked with enlargement of brain ventricles but not with shunt response.

The diagnosis of iNPH is presently based on typical clinical characteristics and radiologic presentation. In addition, different prognostic tests are used to evaluate the potential shunt benefit, but no biomarkers have been found to help in the differential diagnostics. The current vague diagnostic criteria of iNPH1,2 should be noted in the interpretation of the current results and further genetic studies on iNPH. These include the definition of the diagnosis, heterogeneity of the disease course and variable radiologic features, and common comorbid neurodegenerative diseases.4 This poses a challenge for the differential diagnostics of iNPH, and both false and missed diagnoses are likely to be common. Potentially, the genetic information could, in the future, be included in different risk calculators (e.g., reference 23) to provide clinician tools that help decide referrals concerning these types of uncommon diseases.

---

**Figure 1** Flowchart of the study cohort

- **INPH DNA samples (N = 944):** Finnish (567) Norwegian (377)
- **Shunted based on shunting criteria**
  - Finnish (n = 555, 98%)
  - Norwegian (n = 297, 79%)*
- **Not shunted**
  - Finnish (n = 12, 2%)
  - Norwegian (n = 80, 21%)
- **Responsive**
  - Finnish (n = 436, 87%)*
  - Norwegian (n = 258, 87%)
- **Nonresponsive**
  - Finnish (n = 67, 13%)*
  - Norwegian (n = 39, 13%)

*Lost to follow-up (n = 7). CI = confidence interval; OR = odds ratio.

---

**Figure 2** The prevalence of the copy number loss in SFMBT1 among Finnish and Norwegian patients with iNPH

- **Norwegian patients with iNPH**
- **Finnish patients with iNPH**
- **Finnish healthy controls**

The prevalence of the copy number loss in SFMBT1 among Norwegian iNPH patients is 21% (n = 79/377), 9.9% (n = 56/567) among Finnish iNPH patients, and 5.4% (n = 27/508) among Finnish controls. Statistical significance was observed; Norwegian iNPH patients vs Finnish controls (OR = 4.7, CI 95% 3.0–7.5, p < 0.001), Finnish iNPH patients vs Finnish controls (OR = 1.9, CI 95% 1.2–3.1, p = 0.0078), and Norwegian iNPH patients vs Finnish iNPH patients (OR = 2.5, CI 95% 1.7–3.6, p < 0.001). p < 0.05 was considered statistically significant. The Fisher exact test was used for pairwise comparisons. CI = confidence interval; iNPH = idiopathic normal pressure hydrocephalus; OR = odds ratio.
The \textit{SFMBT1} locus has been previously identified to be involved in elevated serum urate levels, fasting glucose, and high blood pressure.\textsuperscript{24–26} The physiologic role of the \textit{SFMBT1} protein is poorly understood but relates to histone binding and is involved in different transcription corepressor activities.\textsuperscript{27,28} However, the \textit{SFMBT1} protein seems to be present in anatomical structures involved with CSF development and circulation such as the choroid plexus, the ependymal cell lining of the ventricles, and the smooth muscle and endothelial cells of the arteries.\textsuperscript{13} A CSF tracer study has revealed disturbed CSF circulation and delayed CSF tracer clearance within the brains of patients with iNPH.\textsuperscript{6} An increasing body of evidence links the pathophysiology behind iNPH to processes taking place at the glia-vascular interface. It has been shown that patients with iNPH showed evidence of alterations in the brain capillary ultrastructure, including alterations in pericytes and endothelial cells.\textsuperscript{29} Furthermore, the perivascular expression of the water channel aquaporin-4 (AQP4) was reduced in iNPH.\textsuperscript{30}

Our study has considerable strengths including a well-characterized large multinational cohort consisting of both shunted and nonshunted patients. The most substantial limitation in the current study is that no healthy Norwegian control individuals were available and that no internal validation was used. The prevalence of the copy number variant could be different among neurologically healthy population. In addition, in the current study, asymptomatic ventriculomegaly was not routinely evaluated from the healthy Finnish controls. Therefore, it is possible that the some of the healthy controls that are carriers for the copy number loss variant in \textit{SFMBT1} have enlarged ventricles but are asymptomatic. This might skew the current result, and the association between iNPH and the copy number loss in \textit{SFMBT1} could be even stronger than reported. Although a strong association between the copy number loss in \textit{SFMBT1} and iNPH was found in both the Japanese and the Caucasian cohorts, there are still limitations to the studies concentrating on the copy number loss in \textit{SFMBT1} and iNPH. First, no nationwide data exist on the prevalence of the copy number loss in \textit{SFMBT1}, and therefore, the controls used provide only a rough estimation of the prevalence in the normal population. Second, the role of the \textit{SFMBT1} gene in the development of cardiovascular diseases needs to be investigated in depth. In addition, the role of \textit{SFMBT1} should be studied in other neurodegenerative diseases to find whether the genetic variation in \textit{SFMBT1} is unique to iNPH. Third, the present results need still to be confirmed in larger multinational cohorts both in cross-sectional and prospective study settings.

Normal pressure hydrocephalus is divided into 3 different groups: idiopathic, where the etiology is unclear, secondary when there is a predisposing factor to be found, and most recently detected familial type, where iNPH is seen also in the first-degree relatives.\textsuperscript{9,11} So far, no difference in the phenotype has been observed between iNPH and familial NPH. Because copy number variation of \textit{SFMBT1} was not enriched in familial iNPH, it does not seem to explain familial aggregation of iNPH, and therefore, other genetic variations are expected to associate with iNPH. The effect of the copy number loss in \textit{SFMBT1} to the clinical phenotype should be described. This might shed light into the different forms of iNPH with so far undistinguishable phenotypes.

It has been reported that some of the asymptomatic people with ventriculomegaly are carriers for the copy number loss in \textit{SFMBT1}.\textsuperscript{13} Ventriculomegaly is a key radiologic finding in iNPH, and Evans Index >0.3 is included as a requirement in the diagnostic criteria of iNPH,\textsuperscript{12} although it has been recently suggested that the cutoff value for ventricular enlargement should be age and sex dependent and the pathologic lower limit of Evan’s Index increased to >0.32.\textsuperscript{31} It has been suggested that people who are asymptomatic with enlarged ventricles are at an increased risk of developing iNPH, and it has been reported

---

**Table 4 Prevalence of hypertension and diabetes**

<table>
<thead>
<tr>
<th>Hypertension(^a)</th>
<th>Finnish iNPH patients</th>
<th>Norwegian iNPH patients</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>\textit{SFMBT1} carrier, n (%)</td>
<td>\textit{SFMBT1} noncarrier, n (%)</td>
</tr>
<tr>
<td>Yes</td>
<td>29 (52)</td>
<td>309 (61)</td>
</tr>
<tr>
<td>No</td>
<td>27 (48)</td>
<td>198 (39)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Diabetes(^b)</th>
<th>Finnish iNPH patients</th>
<th>Norwegian iNPH patients</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>\textit{SFMBT1} carrier, n (%)</td>
<td>\textit{SFMBT1} noncarrier, n (%)</td>
</tr>
<tr>
<td>Yes</td>
<td>12 (21)</td>
<td>156 (31)</td>
</tr>
<tr>
<td>No</td>
<td>43 (77)</td>
<td>356 (69)</td>
</tr>
</tbody>
</table>

Abbreviations: CI = confidence interval; iNPH = idiopathic normal pressure hydrocephalus. NS: nonsignificant p > 0.05. p values are calculated using the Fisher exact test without correction for multiple testing.\(^a\) Data missing from 4 Finnish patients.\(^b\) Data missing from 3 Finnish patients.
that in the Japanese population, 25% of people with asymptomatic ventriculomegaly will eventually develop iNPH. However, the cohort sizes have been limited in the studies in which the connection between AVIM and iNPH has been proposed. Therefore, no universal consensus on this matter exists.

The prevalence of the copy number loss in SFMBT1 could be increased among the families in which iNPH is frequently observed, and therefore, first-degree relatives of patients with iNPH should be included in future genetic studies. It might be that the copy number loss in SFMBT1 is a risk gene for iNPH but requires other unknown triggering risk factors to result in clinical disease.

Future studies are still urgently needed to elucidate the genetics of iNPH. Understanding even some of the pathologic processes causing iNPH provides possibilities to develop targeted or even preventive therapies in the future. This study encourages functional studies on SFMBT1 to clarify the role in the disease process of iNPH.

**Author contributions**

V.E. Korhonen: study concept and design, data acquisition, data analysis and interpretation, and drafting of the manuscript. S. Helisalmi: study concept and design, data acquisition, and critical revision of the manuscript for important intellectual content. A. Jokinen, I. Jokinen, J.-M. Lehtola, M. Oinas, K. Lönnrot, C. Avellan, A. Kottkansalo, J. Frantzen, J. Rinne, A. Ronkainen, M. Kauppinnen, and A. Junkkari: data acquisition and critical revision of the manuscript for important intellectual content. M. Hiltunen and H. Soininen: critical revision of the manuscript for important intellectual content. M. Kurki: critical revision of the manuscript for important intellectual content (statistics). J.E. Jääskeläinen, A.M. Koivisto, H. Sato H, and T. Kato: critical revision of the manuscript for important intellectual content. P.K. Eide and V. Leinonen: study concept and design, data acquisition, critical revision of the manuscript for important intellectual content, and study supervision.

**Acknowledgment**
The authors acknowledge Marjo Laitinen for her help in setting up the qPCR method and RN Marita Parviainen for managing the KUH iNPH register.

**Study funding**

This work was supported by the Academy of Finland (no 307866), the Sigrid Juselius Foundation, the Kuopio University Hospital Research Fund, the Kuopio University Hospital VTR fund, the Emil Aaltonen Foundation, the Cultural Foundation of Finland, the North Savo Regional Fund, the Olvi Foundation, and the Finnish Medical Association. In Norway, the study was supported by grants from Health South-East, Norway (grant 2011067).

**Disclosure**

V.E. Korhonen has received research support from the Kuopio University Hospital Research Fund, the Maire Taponen Foundation, the University of Eastern Finland, the Olvi Foundation, the Emil Aaltonen Foundation, the Finnish Cultural Foundation, the North Savo Regional fund, and the Finnish Medical Association. S. Helisalmi, A. Jokinen, I. Jokinen, J.-M. Lehtola, M. Oinas, and K. Lönnrot report no disclosures. C. Avellan has received research support from the Maire Taponen Foundation, Lastentautien tutkimussäätiö, Stiftelsen Dorothea Olivia, Karl Walter och Jarl Walter Perklens minne, and Svenska kulturfonden. A.E. Kotkansalo reports no disclosures. J. Frantzen serves/has served on the scientific advisory board of and as a consultant to Bonalive Biomaterials Ltd. J. Rinne, A. Ronkainen, and M. Kauppinen report no disclosures. A. Junkkari has received research support from the state research fund (VTR), Kuopio University Hospital (KUH), the University of Eastern Finland (UEF), the Finnish Cultural Foundation, and the Maire Taponen Foundation. M. Hiltunen serves/has served on the editorial boards of the *Journal of Alzheimer’s Disease*, *Journal of Alzheimer’s Disease & Parkinsonism*, and *The Scientific World Journal*. H. Soininen serves/has served on the scientific advisory board of AC Immune and serves/has served on the editorial board of the *Journal of Alzheimer’s Disease*. M. Kurki reports no disclosures. J.E. Jääskeläinen serves/has served on the editorial board of *Acta Neurochirurgica*; has received research support from the Finnish Academy of Sciences, the Juho Vainio Foundation Päivikki, the Sakari Sohlberg Foundation, and Kuopio University Hospital. A.M. Koivisto, H. Sato, T. Kato, A.M. Remes, and P.K. Eide report no disclosures. V. Leinonen has received funding for travel and/or speaker honoraria from B. Braun Aesculap; serves/has served on the editorial board of the *Journal of Alzheimer’s Disease*; and has received research support from NeuroVision Imaging, LLC, and Kuopio University Hospital. Full disclosure form information provided by the authors is available with the full text of this article at Neurology.org/NG.

**Publication history**

Received by *Neurology: Genetics* May 30, 2018. Accepted in final form October 9, 2018.

**References**


Copy number loss in SFMBT1 is common among Finnish and Norwegian patients with iNPH
Ville E. Korhonen, Seppo Helisalmi, Aleksi Jokinen, et al.
Neurol Genet 2018;4;
DOI 10.1212/NXG.0000000000000291

This information is current as of December 3, 2018